City

Seoul (1)

Condition

SCLC, Recurrent (1)

Overall Status

Terminated (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Se-Hoon Lee (1)

Collaborator

Intervention

durvalumab+azd2811 to sclc patients (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Other (1)

Study Type

Interventional (1)

sclc, recurrent

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

SCLC, Recurrent Trial in Seoul (Durvalumab+AZD2811 to SCLC patients)

Terminated

SCLC, Recurrent

Durvalumab+AZD2811 to SCLC patients

Seoul, Gangnam-gu, Korea, Republic of

Samsung Medical Center

Feb 8, 2022